A Turkish study extended these findings by showing that galectin-3 levels were significantly increased among patients with severe COVID-19 compared to non-severe cases and that galectin-3 levels were higher in patients with COVID-19 compared to healthy controls (median of severe COVID-19, 415.31 pg/mL; IQR, 122.81–1622.23 vs. median of non-severe, 326.33 pg/mL; IQR, 100.09–1271.04 vs. median of healthy controls 243.13 pg/mL, 166.57–380.41) [101]. Here, LGALS3 is linked to COVID-19.